Modern Setup Host Windows 10
Kroger Feedback


NAFTIN Gel 2% For Treatment of Interdigital Tinea Pedis


Dr. Linda Stein-Gold shares clinical information on the efficacy of NAFTIN Gel 2% in the treatment of interdigital tinea pedis.  The lecture was sponsored by MERZ Pharma.



At the SDPA Fall 2014 conference, Dr. Linda Stein-Gold lectured on the clinical management of Tinea Pedis and provided an update on the cutting edge research that approves NAFTIN Gel 2% for the treatment of interdigital tinea pedis.  Her lecture was sponsored by MERZ pharmaceuticals.

Dr. Stein-Gold began her talk with statistics demonstrating the prevalence of tinea pedis in the United States.  She stated that 26.5 million people have tinea pedis infections each year in the US, and 45% of those with tinea will suffer from it in episodes greater than 10 years.

Tinea Pedis is more common in men than in women and is one of the top five reasons for physician visits in the US.  Potential risk factors are immunological predisposition and frequent contact with public floors containing fungal elements.  NAFTIN Gel 2% is an effective allylamine antifungal proven efficacious for the treatment of tinea pedis.

In one study, Naftin Gel 2% or a vehicle gel was applied once daily for two weeks to affected areas.  Evaluations were made at baseline, week 2, week 4, and week 6.  NAFTIN showed superiority to the vehicle at 6 weeks in completely curing and showed improved response rates in interdigital-type tinea pedis after 2 weeks of treatment.  At 6 weeks, 77.5% of participants saw clinical success with NAFTIN compared to 32.9% on the vehicle.

In terms of warnings and safety information, studies have shown that NAFTIN is well-tolerated for patients 12 years old and above.  If redness or irritation develops, treatment should be discontinued.  The most common adverse reaction from clinical trial was application site reaction which occurred at the rate of 2%.  NAFTIN Gel 2% is not indicated for Moccasin Type tinea pedis but has shown positive efficacy response rates in clinical trials.

Image: Tobias Lindman

Our Sponsors